GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vanucizumab   Click here for help

GtoPdb Ligand ID: 9132

Synonyms: RG-7221 | RG7221 | RO5520985
Compound class: Antibody
Comment: Vanucizumab is an investigational bi-specific monoclonal antibody, with potential anti-neoplastic activity being developed by Hoffmann-La Roche [1-2]. Vanucizumab simultaneously targets angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST seuqence analysis reveals 100% matches with peptide sequences claimed in patent US8945552 and likely identify XMab1 and XMab2 as candidates for vanucizumab [1].
No information available.
Summary of Clinical Use Click here for help
Phase 1 clinical trials are underway in patients with advanced/metastatic solid tumors either as monotherapy or combined with RO7009789, an anti-CD40 investigational antibody. Phase 2 trial NCT02141295 is evaluating vanucizumab plus FOLFOX (oxaliplatin with 5-fluorouracil and folinic acid chemotherapy) against FOLFOX plus bevacizumab (an anti-VEGFA, anti-angiogenic antibody) in patients with untreated metastatic colorectal cancer.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
ANGPT2 and VEGFA are both proangiogenic mediators. Blocking the activity of both of these factors at the same time is predicted to provide enhanced anti-angiogenic activity compared to anti-VEGFA therapy alone.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02141295 A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer Phase 2 Interventional Hoffmann-La Roche